Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 7.66
CYNO's Cash to Debt is ranked higher than
61% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. CYNO: 7.66 )
Ranked among companies with meaningful Cash to Debt only.
CYNO' s Cash to Debt Range Over the Past 10 Years
Min: 2.24  Med: 79.15 Max: N/A
Current: 7.66
Equity to Asset 0.78
CYNO's Equity to Asset is ranked higher than
76% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. CYNO: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
CYNO' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.80 Max: 0.87
Current: 0.78
0.48
0.87
Interest Coverage 16.96
CYNO's Interest Coverage is ranked lower than
64% of the 192 Companies
in the Global Medical Devices industry.

( Industry Median: 45.13 vs. CYNO: 16.96 )
Ranked among companies with meaningful Interest Coverage only.
CYNO' s Interest Coverage Range Over the Past 10 Years
Min: 14.7  Med: 9999.00 Max: N/A
Current: 16.96
F-Score: 6
Z-Score: 7.03
M-Score: -2.82
WACC vs ROIC
13.68%
6.81%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 7.99
CYNO's Operating margin (%) is ranked higher than
65% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. CYNO: 7.99 )
Ranked among companies with meaningful Operating margin (%) only.
CYNO' s Operating margin (%) Range Over the Past 10 Years
Min: -27.9  Med: 2.72 Max: 15.75
Current: 7.99
-27.9
15.75
Net-margin (%) 5.20
CYNO's Net-margin (%) is ranked higher than
62% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. CYNO: 5.20 )
Ranked among companies with meaningful Net-margin (%) only.
CYNO' s Net-margin (%) Range Over the Past 10 Years
Min: -31.25  Med: 1.97 Max: 11.67
Current: 5.2
-31.25
11.67
ROE (%) 4.79
CYNO's ROE (%) is ranked higher than
57% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 0.98 vs. CYNO: 4.79 )
Ranked among companies with meaningful ROE (%) only.
CYNO' s ROE (%) Range Over the Past 10 Years
Min: -17.23  Med: 1.76 Max: 14.04
Current: 4.79
-17.23
14.04
ROA (%) 3.71
CYNO's ROA (%) is ranked higher than
64% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: -0.34 vs. CYNO: 3.71 )
Ranked among companies with meaningful ROA (%) only.
CYNO' s ROA (%) Range Over the Past 10 Years
Min: -14.3  Med: 1.34 Max: 11.19
Current: 3.71
-14.3
11.19
ROC (Joel Greenblatt) (%) 29.28
CYNO's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 4.07 vs. CYNO: 29.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CYNO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -54.37  Med: 10.74 Max: 60.47
Current: 29.28
-54.37
60.47
Revenue Growth (3Y)(%) 10.40
CYNO's Revenue Growth (3Y)(%) is ranked higher than
74% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. CYNO: 10.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CYNO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -13.1  Med: 13.70 Max: 24.8
Current: 10.4
-13.1
24.8
EBITDA Growth (3Y)(%) 13.50
CYNO's EBITDA Growth (3Y)(%) is ranked higher than
68% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. CYNO: 13.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CYNO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -74  Med: 16.10 Max: 87.3
Current: 13.5
-74
87.3
EPS Growth (3Y)(%) -4.20
CYNO's EPS Growth (3Y)(%) is ranked lower than
55% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. CYNO: -4.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CYNO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -42.1  Med: 1.75 Max: 211.9
Current: -4.2
-42.1
211.9
» CYNO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CYNO Guru Trades in Q2 2015

Robert Olstein 101,000 sh (New)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 10,844 sh (-4.93%)
Chuck Royce 105,000 sh (-55.83%)
» More
Q3 2015

CYNO Guru Trades in Q3 2015

Ken Fisher 94,601 sh (New)
Paul Tudor Jones 6,800 sh (New)
Chuck Royce 105,000 sh (unchged)
Mario Gabelli 10,844 sh (unchged)
Robert Olstein 101,000 sh (unchged)
» More
Q4 2015

CYNO Guru Trades in Q4 2015

Ken Fisher 114,213 sh (+20.73%)
Mario Gabelli 10,844 sh (unchged)
Paul Tudor Jones Sold Out
Robert Olstein 56,000 sh (-44.55%)
Chuck Royce 1,500 sh (-98.57%)
» More
Q1 2016

CYNO Guru Trades in Q1 2016

Steven Cohen 535,400 sh (New)
Joel Greenblatt 58,566 sh (New)
Paul Tudor Jones 5,052 sh (New)
Ken Fisher 114,213 sh (unchged)
Chuck Royce Sold Out
Mario Gabelli 10,581 sh (-2.43%)
Robert Olstein 49,600 sh (-11.43%)
» More
» Details

Insider Trades

Latest Guru Trades with CYNO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:LDRH, NAS:ZLTQ, NAS:BABY, OTCPK:BSNRF, NAS:CNMD, NYSE:GB, NAS:INGN, OTCPK:SKUNF, OTCPK:IOBCF, NAS:MDXG, NAS:OFIX, NAS:SPNC, OTCPK:CSRMF, OTCPK:MCRPF, NAS:VASC, NAS:KTWO, NAS:CSII, OTCPK:JIDG, NAS:HTWR, NAS:WMGI » details
Traded in other countries:C9S.Germany,
Cynosure Inc develops & markets aesthetic treatment systems that enable plastic surgeons, dermatologists & other medical practitioners to perform non-invasive & minimally invasive procedures to remove hair, treat vascular & benign pigmented lesion, etc.

Cynosure Inc was incorporated in July 1991. The Company develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. It has also developed an aesthetic treatment product for the home use market. The Company sells its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Australia, Korea, China, Japan and Mexico and through international distributors in approximately 120 other countries. Its product portfolio is composed of various energy sources including Alexandrite, diode, Nd:YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. It offers single energy source systems as well as workstations that incorporate two or more different types of lasers or pulsed light technologies. It offers multiple technologies and system alternatives at various price points depending mainly on the number and type of energy sources included in the system. Its products are designed to be easily upgradeable to add additional energy sources and handpieces, which provide its customers with technological flexibility as it expand their practices. The Company's latest innovations are SmartLipo system and PicoSure system. The Company's flagship products include Elite, Affirm/SmartSkin, Cynergy, Accolade. The Company sells its aesthetic treatment systems to the traditional physician customer base of dermatologists and plastic surgeons as well as to non-traditional physician customers who are providing aesthetic services using laser and light-based technology. Non-traditional physician customers can include primary care physicians, obstetricians and gynecologists. As of December 31, 2013, the Company owns over 60 United States patents, as well as many United States pending applications and foreign patents and pending applications. It is also joint owners with El.En. of certain patents and pending applications. The Company competes with Cutera, Solta Medical, Syneron Medical, ZELTIQ Aesthetics, Alma Lasers among others. Its products are medical devices subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, or FDA, as well as other regulatory bodies.

Ratios

vs
industry
vs
history
P/E(ttm) 60.03
CYNO's P/E(ttm) is ranked lower than
81% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 26.63 vs. CYNO: 60.03 )
Ranked among companies with meaningful P/E(ttm) only.
CYNO' s P/E(ttm) Range Over the Past 10 Years
Min: 5.41  Med: 35.97 Max: 670.43
Current: 60.03
5.41
670.43
Forward P/E 36.50
CYNO's Forward P/E is ranked lower than
80% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 24.15 vs. CYNO: 36.50 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 60.03
CYNO's PE(NRI) is ranked lower than
81% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 26.92 vs. CYNO: 60.03 )
Ranked among companies with meaningful PE(NRI) only.
CYNO' s PE(NRI) Range Over the Past 10 Years
Min: 5.42  Med: 35.78 Max: 630.2
Current: 60.03
5.42
630.2
Price/Owner Earnings (ttm) 40.54
CYNO's Price/Owner Earnings (ttm) is ranked lower than
63% of the 108 Companies
in the Global Medical Devices industry.

( Industry Median: 31.00 vs. CYNO: 40.54 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CYNO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 16.47  Med: 40.34 Max: 195.05
Current: 40.54
16.47
195.05
P/B 2.70
CYNO's P/B is ranked higher than
53% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. CYNO: 2.70 )
Ranked among companies with meaningful P/B only.
CYNO' s P/B Range Over the Past 10 Years
Min: 0.46  Med: 1.83 Max: 4.96
Current: 2.7
0.46
4.96
P/S 3.07
CYNO's P/S is ranked higher than
51% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.99 vs. CYNO: 3.07 )
Ranked among companies with meaningful P/S only.
CYNO' s P/S Range Over the Past 10 Years
Min: 0.5  Med: 2.10 Max: 5.45
Current: 3.07
0.5
5.45
PFCF 36.93
CYNO's PFCF is ranked lower than
66% of the 95 Companies
in the Global Medical Devices industry.

( Industry Median: 29.37 vs. CYNO: 36.93 )
Ranked among companies with meaningful PFCF only.
CYNO' s PFCF Range Over the Past 10 Years
Min: 8.58  Med: 28.69 Max: 164.2
Current: 36.93
8.58
164.2
POCF 26.20
CYNO's POCF is ranked lower than
64% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 19.79 vs. CYNO: 26.20 )
Ranked among companies with meaningful POCF only.
CYNO' s POCF Range Over the Past 10 Years
Min: 5.75  Med: 22.90 Max: 1420
Current: 26.2
5.75
1420
EV-to-EBIT 35.64
CYNO's EV-to-EBIT is ranked lower than
68% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 20.28 vs. CYNO: 35.64 )
Ranked among companies with meaningful EV-to-EBIT only.
CYNO' s EV-to-EBIT Range Over the Past 10 Years
Min: -183  Med: 8.40 Max: 311.7
Current: 35.64
-183
311.7
EV-to-EBITDA 21.18
CYNO's EV-to-EBITDA is ranked lower than
60% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 17.82 vs. CYNO: 21.18 )
Ranked among companies with meaningful EV-to-EBITDA only.
CYNO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -305.3  Med: 15.10 Max: 441.3
Current: 21.18
-305.3
441.3
PEG 0.61
CYNO's PEG is ranked higher than
88% of the 74 Companies
in the Global Medical Devices industry.

( Industry Median: 3.22 vs. CYNO: 0.61 )
Ranked among companies with meaningful PEG only.
CYNO' s PEG Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 0.61
Shiller P/E 216.53
CYNO's Shiller P/E is ranked lower than
98% of the 44 Companies
in the Global Medical Devices industry.

( Industry Median: 40.52 vs. CYNO: 216.53 )
Ranked among companies with meaningful Shiller P/E only.
CYNO' s Shiller P/E Range Over the Past 10 Years
Min: 95.17  Med: 170.48 Max: 231.91
Current: 216.53
95.17
231.91
Current Ratio 3.03
CYNO's Current Ratio is ranked higher than
53% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.88 vs. CYNO: 3.03 )
Ranked among companies with meaningful Current Ratio only.
CYNO' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 4.07 Max: 7.09
Current: 3.03
1.67
7.09
Quick Ratio 2.10
CYNO's Quick Ratio is ranked higher than
50% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. CYNO: 2.10 )
Ranked among companies with meaningful Quick Ratio only.
CYNO' s Quick Ratio Range Over the Past 10 Years
Min: 0.87  Med: 3.36 Max: 5.83
Current: 2.1
0.87
5.83
Days Inventory 181.88
CYNO's Days Inventory is ranked lower than
67% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 136.99 vs. CYNO: 181.88 )
Ranked among companies with meaningful Days Inventory only.
CYNO' s Days Inventory Range Over the Past 10 Years
Min: 157.29  Med: 176.34 Max: 289.61
Current: 181.88
157.29
289.61
Days Sales Outstanding 39.14
CYNO's Days Sales Outstanding is ranked higher than
90% of the 271 Companies
in the Global Medical Devices industry.

( Industry Median: 68.67 vs. CYNO: 39.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYNO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 42.42  Med: 55.97 Max: 92.51
Current: 39.14
42.42
92.51
Days Payable 61.85
CYNO's Days Payable is ranked higher than
50% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 61.70 vs. CYNO: 61.85 )
Ranked among companies with meaningful Days Payable only.
CYNO' s Days Payable Range Over the Past 10 Years
Min: 23.04  Med: 53.49 Max: 84.75
Current: 61.85
23.04
84.75

Valuation & Return

vs
industry
vs
history
Price/Net Cash 49.14
CYNO's Price/Net Cash is ranked lower than
78% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 16.61 vs. CYNO: 49.14 )
Ranked among companies with meaningful Price/Net Cash only.
CYNO' s Price/Net Cash Range Over the Past 10 Years
Min: 1.5  Med: 5.58 Max: 73.23
Current: 49.14
1.5
73.23
Price/Net Current Asset Value 6.80
CYNO's Price/Net Current Asset Value is ranked higher than
51% of the 205 Companies
in the Global Medical Devices industry.

( Industry Median: 6.53 vs. CYNO: 6.80 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CYNO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.73  Med: 2.67 Max: 6.46
Current: 6.8
0.73
6.46
Price/Tangible Book 4.20
CYNO's Price/Tangible Book is ranked lower than
52% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 3.76 vs. CYNO: 4.20 )
Ranked among companies with meaningful Price/Tangible Book only.
CYNO' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.56  Med: 2.25 Max: 4.59
Current: 4.2
0.56
4.59
Price/Projected FCF 2.25
CYNO's Price/Projected FCF is ranked lower than
52% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. CYNO: 2.25 )
Ranked among companies with meaningful Price/Projected FCF only.
CYNO' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.98  Med: 1.54 Max: 2.09
Current: 2.25
0.98
2.09
Price/Median PS Value 1.47
CYNO's Price/Median PS Value is ranked lower than
72% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. CYNO: 1.47 )
Ranked among companies with meaningful Price/Median PS Value only.
CYNO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.32  Med: 0.99 Max: 2.44
Current: 1.47
0.32
2.44
Price/Graham Number 3.35
CYNO's Price/Graham Number is ranked lower than
65% of the 137 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. CYNO: 3.35 )
Ranked among companies with meaningful Price/Graham Number only.
CYNO' s Price/Graham Number Range Over the Past 10 Years
Min: 0.65  Med: 1.83 Max: 9.71
Current: 3.35
0.65
9.71
Earnings Yield (Greenblatt) (%) 2.85
CYNO's Earnings Yield (Greenblatt) (%) is ranked higher than
64% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. CYNO: 2.85 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYNO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 3.80 Max: 1687.3
Current: 2.85
0.3
1687.3

More Statistics

Revenue (TTM) (Mil) $359.2
EPS (TTM) $ 0.81
Beta1.62
Short Percentage of Float6.28%
52-Week Range $29.00 - 53.33
Shares Outstanding (Mil)23.52

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 409 444
EPS ($) 1.31 1.93
EPS w/o NRI ($) 1.31 1.93
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NAS:CYNO

Headlines

Articles On GuruFocus.com
Steven Cohen Invests in Cynosure Apr 26 2016 
Robert Olstein's Olstein Strategic Opportunities Fund Q4 Commentary Mar 11 2016 
Cynosure Inc. (CYNO) CFO Timothy W Baker buys 2,500 Shares Feb 27 2009 
Cynosure Inc. (CYNO) CEO Michael R Davin buys 2,500 Shares Feb 27 2009 
Cynosure: A Value Play on Vanity Jan 18 2009 

More From Other Websites
ETF’s with exposure to Cynosure, Inc. : June 30, 2016 Jun 30 2016
Cynosure, Inc. :CYNO-US: Earnings Analysis: Q1, 2016 By the Numbers : June 28, 2016 Jun 28 2016
Cynosure to Ring NASDAQ Stock Market Closing Bell to Celebrate 25 Year Anniversary Jun 16 2016
Cynosure to Ring NASDAQ Stock Market Closing Bell to Celebrate 25 Year Anniversary Jun 16 2016
ETF’s with exposure to Cynosure, Inc. : June 13, 2016 Jun 13 2016
Here Is Why These 2 Medical Equipment Stocks Are Buys for Growth Jun 06 2016
5 stocks to watch May 26 2016
Cynosure Announces Planned Retirement of Timothy W. Baker as President, Chief Financial Officer and... May 25 2016
Cynosure (CYNO) Up on FDA Approval for New 1064nm LDS May 25 2016
CYNOSURE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... May 25 2016
Cynosure Announces Planned Retirement of Timothy W. Baker as President, Chief Financial Officer and... May 25 2016
Cynosure Gets FDA Approval To Market New PicoSure Energy Delivery System For Tattoos And Pigmented... May 24 2016
Cynosure Receives FDA Clearance to Market New PicoSure® Energy Delivery System for Tattoos and... May 24 2016
Cynosure Receives FDA Clearance to Market New PicoSure® Energy Delivery System for Tattoos and... May 24 2016
CYNOSURE INC Financials May 19 2016
CYNOSURE INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... May 16 2016
CYNOSURE INC Files SEC form 10-Q, Quarterly Report May 10 2016
ETF’s with exposure to Cynosure, Inc. : May 9, 2016 May 09 2016
ETF’s with exposure to Cynosure, Inc. : April 28, 2016 Apr 28 2016
Why Do Fund Managers Find This Top Medical Device Maker ‘Infectious’? Apr 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)